What TB-500 costs

What TB-500 sells for is driven by four things, and only one of them is about the material itself. This page sets out all four, and explains how to compare two listings without being misled by the one that varies most.

It carries no prices, and that is deliberate rather than an omission. This site sells nothing and links to no seller, and the editorial standard it publishes under puts prices on the list of things it does not print, alongside carts, order buttons and stock indicators.

What is worth knowing is structural, and this compound has a structural quirk. Two different substances are sold under the one name, the free base and the acetate salt, and FDA records suppliers reusing the free base's identifiers for the acetate. Comparing two listings can therefore be comparing two different materials.

What drives the price

Which substance is in the container is the first factor and the one least often stated. FDA treats TB-500 free base and TB-500 acetate as separate bulk drug substances with separate specifications, and records that suppliers reuse the free base's CAS number for the acetate. A listing that names only TB-500 has not answered the question.

Container size is the second, and it is the reason a comparison between two listings usually needs arithmetic before it means anything. Cost per unit weight and cost per container are different quantities and only the first one says anything.

Synthesis cost is the third, and it is why this compound is inexpensive relative to longer peptides. Seven residues is seven coupling steps, and the acetyl cap adds a step and a specification rather than a difficulty. That low floor is also why the market has room for material that was never independently tested.

Testing is the fourth and the least visible. A certificate carrying an independent identity test, a net peptide content figure and confirmation of which salt is present costs real money to produce. A certificate carrying none of those costs almost nothing.

Where it is sold

This site links to no seller today, so the table below is empty. The moment any outbound store link appears on this page, three things ship in the same deploy: the link carries rel="sponsored nofollow", a visible disclosure sits beside it naming the relationship as common ownership rather than a commission, and the same disclosure goes into the footer of every page. That is written down in the editorial policy before there is anything to disclose, which is the only time such a commitment is worth making.

How to read a price in this market

A price says nothing about identity or content. For this compound that gap is wider than usual, because the name covers more than one substance and FDA has recorded multiple salts and derivatives sold under it.

Cost per unit weight is the only comparison that carries information, and it is only computable where the container's contents are stated. Net peptide content is a separate figure from container weight and is reported separately if at all.

Research-use-only labelling does not change what a sale is. FDA has rejected that framing where evidence from a seller's own website showed intent for human use, reasoning from the websites themselves. The dated regulatory record for this compound, with its documents, is in the regulatory section of the evidence review.

This site links to no seller today. When that changes, the link will carry rel sponsored nofollow, a visible disclosure will sit beside it naming the relationship as common ownership rather than a commission, and the same disclosure will go into the footer of every page in the same deploy.

What a certificate of analysis proves, and what it does not, is covered in the sourcing section of the evidence review.

Frequently asked questions